BLIS study: a feasibility randomised controlled trial assessing compliance, acceptability and colonisation with different dosing regimens of the probiotic supplement Streptococcus salivarius K12 (Bactoblis) in adults in England.
BMJ OpenSep 15, 2026 (epub)
Christopher R Wilcox, David W Cleary, Maclyn Augustine et al.
✦ AI-curated · Sources linked
In 30 seconds
The BLIS study was a randomized controlled trial assessing the colonization, acceptability, and feasibility of two dosing regimens of the probiotic Streptococcus salivarius K12 in adults with recurrent sore throats in England. The study found that colonization was significantly higher with daily dosing (85.7% on day 7) compared to weekly dosing (13.6% on day 7), although colonization did not persist after cessation of dosing.
Key findings
- Colonization with SsK12 was found in 85.7% of daily dosing participants on day 7.
- Only 13.6% of weekly dosing participants showed colonization on day 7.
- 85.0% of weekly and 96.2% of daily dosing participants reported the regimen as easy to follow.
Why it matters
Understanding the optimal dosing regimen for probiotics like SsK12 can inform future clinical trials aimed at preventing recurrent sore throat and tonsillitis, potentially improving patient outcomes in primary care settings.